jpnn.com, JAKARTA - The Cell and Growth Factor Biotechnology (CGBio) company will enter the implant and bone replacement market in Indonesia.
CGBIO CEO Hyun Seung Yu said Indonesia had a high demand for bone implants.
ALSO SEE: Benefits of Cinnamon for Your General Health, Sexual Life
According to South Korea's National Institute for Food and Drug Safety Evaluation, the compound annual growth rate (CAGR) of the Indonesian medical device market is estimated to grow to 11.4 percent or reach US$2 billion in 2024 from 2019.
Hyun Seung Yu stated that the company's entry into the Indonesian market was marked by the launch of NOVOSIS.
ALSO SEE: Indonesia Rewards Health Workers With Free Staycation
"We are very pleased that NOVOSIS and Excelos Injects with their innovative bone fusion performance have entered the Indonesian implant and bone replacement market with high growth potential," he said.
"CGBio will continue to strive to supply superior products to the world in line with its mission to contribute to leading people to live young and healthy lives with advanced regenerative medical technology," he added.
ALSO SEE: 5 Things Diabetics Must Do Every Morning to Control Blood Sugar
The company, which is specifically engaged in regenerative medicine, will market a bone replacement containing rhBMP-2, Recombinant Human Bone Morphogenetic Protein-2, and Excelos Inject.
Hyun Seung Yu explained that NOVOSIS was rhBMP-2, the first in South Korea and the second in the world. This technology is helpful for spinal fusion and upper and lower limb fractures.
He also said that Excelos Inject was a bone replacement medical technology made from tens of micrometers in size of spherical beta-tricalcium phosphate.
The implants can be used by imprinting on the damaged area of bone, then increasing ease of use and slowly being absorbed over time. (mcr10/mcr20/jpnn)
This news has been broadcast on JPNN.com with the title: Siap-Siap, Inovasi Implan Tulang Segera Hadir di Indonesia